article · Discover Applied Sciences
Abstract Camptothecin (CPT) is one of the common chemotherapies for tumors, for its superior affinity for inhibiting the Topoisomerase I activity via stabilizing the enzyme–DNA ternary complex, thus precluding the relaxation of DNA in the frequently replicated cells. CPT was initially derived from the bark of chinese Happy tree plants “ Camptotheca acuminata ”. However, availability of the CPT and their derivatives is the main challenge that halts the further implementation of this compound. The fungal biosynthetic potency of CPT raises the prospective for the production of CPT, due to their short lifespan and feasibility of bulk biomass bioprocessing, nevertheless, weakening of the CPT productivity with the fungal storage consecutive subculturing are the challenge. So, this review was to unravel the biosynthetic potency of CPT and their molecular regulatory processes to sustain the CPT productivity by fungi by exploring the rate-limiting enzymes, epigenetic regulators and transcriptional factors of CPT biosynthesis. As well as, to explore the expression of CPT biosynthetic gene clusters regarding to chromatin remodeling, microbial-microbial crosstalk, in relation to deciphering the CPT biosynthesis gene cluster by fungi.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1007/s42452-026-09234-4
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.